Daniel B. Soland - 30 Sep 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: Director
Issuer ticker: KALV
Reported as of: 30 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Oct 2021, 16:56:56 UTC
Prior SEC filing: 12 Jul 2021
Next SEC filing: 26 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Daniel B. Soland filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 01 Oct 2021.

Key facts

This page summarizes Daniel B. Soland's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Oct 2021, 16:56.

Change

Previous filing in this sequence was filed on 12 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALV transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 30 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $17.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.